Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males

Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males / Jennifer D. Wallace, Ross C. Cuneo, Per Arne Lundberg, Thord Rosén, Jens Otto Lunde Jørgensen, Salvatore Longobardi, Nicola Keay, Luigi Sacca, Jens Sandahl Christiansen, Bengt-Åke Bengtsson, Peter H. Sönksen. - (The Journal of Clinical Endocrinology & Metabolism 85 (2000) 1 (1 January); p. 124-133)

  • PMID: 10634375
  • DOI: 10.1210/jcem.85.1.6262


Abstract

To examine the interactions between acute exercise and GH on markers of bone and collagen turnover and to assess the potential for detecting GH abuse in athletes using these markers, we studied 17 aerobically trained males (age, 26.9+/-1.5 yr). Sequential studies of exercise, GH administration, and GH withdrawal were undertaken. A randomized, controlled study of rest vs. exercise showed that exercise did not change serum osteocalcin; other markers of formation increased transiently (each P<0.001): bone-specific alkaline phosphatase (+16.1%), carboxyterminal propeptide of type I procollagen (+14.1%), and procollagen III N-terminal extension peptide (+5.0%). The carboxyterminal cross-linked telopeptide of type I collagen, a bone resorption marker, increased 9.7% (P = 0.018) in response to exercise. A randomized, double blind, placebo-controlled, parallel study of recombinant human GH treatment (0.15 IU/kg x day) for 1 week increased serum osteocalcin (net increase preexercise, +/-10.0%; P = 0.017), carboxyterminal propeptide of type I procollagen (+17.6%; P = 0.002), procollagen III N-terminal extension peptide (+48.4%; P = 0.001), and carboxyterminal cross-linked telopeptide of type I collagen (53.3%; P = 0.009). Disappearance half-times after cessation of recombinant human GH for pre- and postexercise markers ranged from 248-770 h. We conclude 1) endurance exercise transiently activates bone and collagen turnover; 2) brief GH administration results in similar but quantitatively greater augmentation; and 3) these data will assist in designing a GH detection strategy.

Original document

Parameters

Science
Study
Date
1 January 2000
People
Bengtsson, Bengt-Åke
Christiansen, Jens Sandahl
Cuneo, Ross C.
Keay, Nicola
Longobardi, Salvatore
Lundberg, Per Arne
Lunde Jørgensen, Jens Otto
Rosén, Thord
Sacca, Luigi
Sönksen, Peter H.
Wallace, Jennifer D.
Country
Australia
Denmark
Italy
Sweden
United Kingdom
Language
English
Other organisations
Aarhus Universitetshospital - Aarhus University Hospital
Azienda Ospedaliera Universitaria Federico II - Federico II University Hospital
Sahlgrenska Universitetssjukhuset - Sahlgrenska University Hospital
St. Thomas’s Hospital
University of Queensland (UQ)
Analytical aspects
Testing method development
Doping classes
S2. Peptide Hormones, Growth Factors
Substances
Growth hormone (GH)
Document category
Scientific article
Document type
Pdf file
Date generated
29 June 2020
Date of last modification
7 September 2020
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin